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Background: Coexpression of CD160 and PD-1 on HIV-specific CD8+ T-cells defines a highly exhausted T-cell
subset. CD160 binds to Herpes Virus Entry Mediator (HVEM) and blocking this interaction with HVEM antibodies
reverses T-cell exhaustion. As HVEM binds both inhibitory and activatory receptors, our aim in the current study was
to assess the impact of CD160-specific antibodies on the enhancement of T-cell activation.
Methods: Expression of the two CD160 isoforms; glycosylphosphatidylinositol-anchored (CD160-GPI) and the
transmembrane isoforms (CD160-TM) was assessed in CD4 and CD8 primary T-cells by quantitative RT-PCR and
Flow-cytometry. Binding of these isoforms to HVEM ligand and the differential capacities of CD160 and HVEM
specific antibodies to inhibit this binding were further evaluated using a Time-Resolved Fluorescence assay (TRF).
The impact of both CD160 and HVEM specific antibodies on enhancing T-cell functionality upon antigenic stimulation
was performed in comparative ex vivo studies using primary cells from HIV-infected subjects stimulated with HIV
antigens in the presence or absence of blocking antibodies to the key inhibitory receptor PD-1.
Results: We first show that both CD160 isoforms, CD160-GPI and CD160-TM, were expressed in human primary
CD4+ and CD8+ T-cells. The two isoforms were also recognized by the HVEM ligand, although this binding was less
pronounced with the CD160-TM isoform. Mechanistic studies revealed that although HVEM specific antibodies
blocked its binding to CD160-GPI, surprisingly, these antibodies enhanced HVEM binding to CD160-TM, suggesting
that potential antibody-mediated HVEM multimerization and/or induced conformational changes may be required
for optimal CD160-TM binding. Triggering of CD160-GPI over-expressed on Jurkat cells with either bead-bound
HVEM-Fc or anti-CD160 monoclonal antibodies enhanced cell activation, consistent with a positive co-stimulatory
role for CD160-GPI. However, CD160-TM did not respond to this stimulation, likely due to the lack of optimal HVEM
binding. Finally, ex vivo assays using PBMCs from HIV viremic subjects showed that the use of CD160-GPI-specific
antibodies combined with blockade of PD-1 synergistically enhanced the proliferation of HIV-1 specific CD8+
T-cells upon antigenic stimulation.
Conclusions: Antibodies targeting CD160-GPI complement the blockade of PD-1 to enhance HIV-specific T-cell
responses and warrant further investigation in the development of novel immunotherapeutic approaches.
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Negative immune regulators such as Programmed Death-1
(PD-1) and Cytotoxic T Lymphocyte Antigen 4 (CTLA-4)
are part of a large network of immune checkpoints that are
tightly regulated in order to limit exaggerated immune re-
sponses and prevent autoimmunity [1-4]. However, in
some instances such as persistent antigenic stimulation
during chronic HIV or other viral infections, these
negative regulators accumulate progressively on the cell
surface of total and Ag-specific T and B cells [5-9]. Ex-
pression and engagement of these negative regulators
with their cognate ligands down modulate cell functions
in a hierarchical manner with cell proliferation and IL-2
production being lost at earlier stages whereas IFNγ and
TNFα are lost at later stages in what is referred to as im-
mune exhaustion [10,11].
PD-1, a central negative regulatory molecule was one
of the early studied mediators of immune exhaustion in
chronic infectious diseases, particularly HIV-1 infection
[6,7] and in animal viral chronic infectious models [12].
A large body of evidence indicates that loss of function
is not simply associated with PD-1 expression alone. Other
characteristics such as the level of PD-1 expression and/or
its co-expression with other negative modulators may
better identify functionally impaired T-cells [13,14].
Co-expression of CD160 with PD-1, 2B4 and KLRG1
on HCV-specific CD8+ T-cells was associated with dimin-
ished cell functions and an intermediate differentiation
stage [15]. Similarly, co-expression of CD160 and PD-1
was also shown to define a subset of HIV-specific CD8+
T-cells with advanced dysfunction characterized by up-
regulation of different inhibitory pathways and down-
regulation of the NF-ΚB transcriptional node [14].
CD160 is a glycosylphosphatidylinositol (GPI)-anchored
protein member of the Ig superfamily with a restricted
expression profile that is limited to CD56dim CD16+ NK
cells, NKT-cells, γδ T-cells, cytotoxic CD8+ T-cells lack-
ing the expression of CD28, a small fraction of CD4+ T-
cells and all intraepithelial lymphocytes [16-18]. Binding
of CD160 to both classical and non-classical MHC I
enhances NK and CD8+ CTL functions [19-22]. However,
engagement of CD160 by the Herpes Virus Entry Medi-
ator (HVEM) was shown to mediate inhibition of CD4+
T-cell proliferation and TCR-mediated signaling [23].
HVEM protein is a bimolecular switch that binds both
co-stimulatory LT-α/LIGHT and co-inhibitory receptors
BTLA/CD160 (Reviewed by del Rio et al., [24]). The bind-
ing of LIGHT on T-cells to HVEM, a co-stimulatory cell
surface protein expressed by immature DCs and activated
T-cells, induces potent inflammatory signals and a Th1-
mediated response [25]; in turn, the binding of LIGHT to
HVEM on T-cells elicits activation and survival signals
through the induction of NF-ΚB and AP1 [26,27]. In con-
trast, binding of HVEM to BTLA expressed by T-cellsengages a potent negative signaling pathway involving
both SHP-1 and SHP-2 phosphatases and effectively at-
tenuates TCR activation [28,29]. During chronic HIV
infection, ex vivo blockade of the HVEM network with
polyclonal antibodies to HVEM enhances HIV-specific
CD8+ T-cell functions, such as cell proliferation and
cytokine production [14]. The functional effects of
HVEM binding is probably influenced by several fac-
tors in addition to the interacting partner, such as cell
types, strength of stimulation and expression kinetics
of the receptor/ligand pairs. Consequently, the interpret-
ation of results based exclusively on HVEM-directed block-
ade may benefit from additional exploration involving the
interacting ligand(s).
As CD160 expression was shown to be specifically up-
regulated on CD8+ T-cells during the chronic phase of HIV
infection, we aimed in the current study to assess the tar-
geting of CD160 receptor on HIV-specific responses. We
evaluated the interaction of the two CD160 isoforms
CD160-GPI and CD160-TM with HVEM ligand, as well
as the impact of targeting CD160, in combination with
anti-PD-1, to provide a beneficial pharmacological effect
on HIV-specific CD8+ T-cells in response.
Materials and methods
Cloning of human CD160-GPI and CD160-TM isoforms
The complete CD160 cDNA sequence was synthesized
in vitro (DNA2.0) and codon-optimized for human ex-
pression. To generate the CD160-GPI and the CD160-TM
expression plasmids, the CD160 sequence was first PCR





CTTG (antisense, CD160-TM). The PCR fragments were
then digested with BglII and XhoI and inserted into the
BamHI/XhoI digested pcDNA3.1/neo(+) vector (Invitro-
gen), downstream of the CMV promoter. Note that BglII
and BamHI produce compatible ends.
Production of stable cell lines
CHO-K1 (ATCC, CCL-61) stable cell lines expressing hu-
man CD160-GPI or CD160-TM were generated by lipofec-
tion of the CD160 expression vectors (pcDNA3.1) into
naïve CHO-K1 cells using Lipofectamine 2000 (Invitrogen).
Transfected cells were incubated at 37°C-5% CO2 in pres-
ence of 800 μg/ml Geneticin and, after a selection of 10–14
days, resistant T-cell colonies were isolated and transferred
into 48-well tissue culture plate. Following incubation at
37°C-5% CO2 to allow for cell growth, cell surface expres-
sion of CD160 was evaluated with a time-resolved fluores-
cence assay (see below for details) using an anti-CD160
(R&D Systems, MAB6700) and an anti-mouse Eu-N1
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of CD160-GPI or CD160-TM were expanded.
Jurkat stable cell lines expressing CD160-GPI or CD160-
TM were also generated by transfecting Jurkat-NFAT-Luc
cells (stably transfected with pGL4.30 NFAT-luciferase
with NFAT enhancer element, Promega, and maintained
with hygromycin selection) with pcDNA3.1/neo(+) vector
encoding the respective CD160 isoform. The CD160-GPI




inserted into the compatible plasmid vector via the under-
scored NheI and NotI restriction sites. The CD160-TM
form was PCR amplified using the CD160-GPI forward
primer in combination with the following NotI-encoding
anti-sense primer: ATAGTTTAGCGGCCGCTCACTAG
TGGAACTGATTCG, and inserted into an NheI-NotI
restricted pcDNA3.1 vector. Jurkat-CD160 positive clones
were selected with Geneticin as described above.
Time-Resolved Fluorescence (TRF) assay
A TRF assay was used to evaluate the capacity of differ-
ent antibodies to inhibit the binding of recombinant hu-
man HVEM-Fc fusion protein (R&D systems, 356-HV/
CF) to cells expressing either CD160-GPI or CD160-
TM. In this assay, naïve CHO-K1 cells (used for back-
ground controls) or CHO-K1 cells expressing CD160
were trypsinized and diluted in F-12 media (Invitrogen)
containing 10% FBS (Hyclone). Cells (40,000 per well)
were then aliquoted in poly-D-lysine treated white 384-
well tissue culture plates and incubated for 20 h at 37°C-
5% CO2. After incubation, supernatant was removed and
cells were washed once with 100 μl of TRF wash buffer
(50 mM Tris pH 7.5, 0.05% Tween, 0.2% BSA, 150 mM
NaCl). Ten μl of either CD160 or HVEM antibodies di-
luted in NaPO4 buffer (50 mM NaPO4 pH 6.6, 150 mM
NaCl, 2% FBS) were added to each well, except for the
background and the no-inhibition controls which re-
ceived 10 μl of NaPO4 buffer, followed by the addition of
40 μl of 1.25 μg/ml HVEM-Fc, also diluted in NaPO4
buffer. The plate was then incubated for 1 h at RT and
the wells were washed 3 times with 100 μl of TRF wash
buffer. Following this wash step, 50 μl of 0.25 μg/ml
anti-human Eu-N1 (Perkin Elmer, 1244–330) diluted in
DELFIA assay buffer (Perkin Elmer, 1244–111) was
added to each well and the plate was incubated for 1 h
at RT. The wells were then washed as above (3 times
100 μl TRF wash buffer) and 50 μl of DELFIA enhance-
ment solution (Perkin Elmer, 1244–105) were added.
After an incubation of 20 min at RT, the fluorescence
signal was monitored using a Wallac Victor microplate
reader (excitation at 340 nm and emission at 615 nm).
The antibodies tested in this assay included CD160 mAbclone CL1-R2 (MBL International), CD160 mAb clone
688327 (R&D), polyclonal anti-HVEM (R&D) and mono-
clonal anti-HVEM clone 94801 (R&D).RNA isolation from cells and quantification
The “RNeasy Kit” (Qiagen) was used to isolate RNA from
cells. The total RNA concentration was determined using
the “Quant-iT RiboGreen® RNA Assay Kit” from Invi-
trogen. The RNA concentration of the samples was de-
termined from the standard curve generated using the
ribosomal RNA standards.Real-time qRT-PCR assays
The “TaqMan EZ RT-PCR kit” (Applied Biosystems;
ABI) was used to perform real-time (RT)-PCR reactions
on a 7500 Real Time PCR System (ABI). Quantification
of cellular CD160 TM RNA from primary T-cells was per-
formed with specific primers (forward: 5’-CCCAAGCA
ATGAGGGTGCTATT-3’, and reverse 5’-GGACATCCT
TTCCAACCTTCTC-3’) and the 5’(FAM)-TCTGCCACC
TTGGTTATTCTCCAGG-(BHQ)3’ probe (Integrated DNA
Technologies; IDT). Quantification of cellular CD160-GPI
RNA was performed with forward: 5’-CAACACCTTGA
GTTCAGCCATA-3’; and reverse primers 5’-GACCAGC
ATTACCCAGACCTT-3’ and the 5’(FAM)-TGAAGGCA
CTCTCAGTTCAGGCTTC-(BHQ)3’ probe (IDT). The
quantification of cellular CD160-GPI RNA was also per-
formed with the “TaqMan® Gene Expression Assays” (ABI)
containing gene-specific probes and primer sets. Quan-
tification of codon-optimized CD160-GPI RNA over-
expressed in Jurkat cells was performed using the following
sense and anti-sense primers: 5’-GGCCATCGTGGACAT
TCAGT-3’; 5’-GTGCCACACCGTACAGATAAGG-3’ with
a 5’(FAM)-CCGGAGGTTGCATCAACATTACAAGC-
(BHQ)3’ probe. The following forward and reverse primers
were used to quantify codon-optimized CD160 TM RNA:
5’-CAAGGCGGAGGAGACTGGAG-3’; 5’-GTGGAACTG
ATTCGAGGACTCT-3’ with the 5’(FAM)-TCACGAGGC
CGGGAGAAATGTTA-(BHQ)3’ probe (IDT). The Ct
values obtained for the RNA assay samples were used
to interpolate an RNA copy number based on the stand-
ard curve, and the RNA copy number was normalized (by
RiboGreen RNA quantification of the RNA extracted from
cells and by GAPDH copy number) and expressed as quan-
tity of copy number/μg of total RNA. The quantification
of cellular GAPDH RNA transcripts was performed with
the following forward and reverse primers (5’-CCTGCAC
CACCAACTGCTTAG-3’, 5’-TGAGTCCTTCCACGATA
CCAA-3’, respectively) and the 5’(FAM)-CCCTGGCCA
AGGTCATCCATG A-(BHQ)3’ probe (IDT). GAPDH
RNA copy number was normalized by RiboGreen RNA
quantification of the RNA extracted from cells. Serial
dilutions of cellular or codon-optimized CD160-TM RNA
El-Far et al. Journal of Translational Medicine 2014, 12:217 Page 4 of 16
http://www.translational-medicine.com/content/12/1/217were used to generate a standard for gene-specific expres-
sion analysis and to determine changes in transcript levels.
Antibodies
FACS analyses used anti-CD3 (V-500), anti-CD4 (BV-605),
anti-CD8 (APC-H7), anti-CD25 (A700), anti-CD134
(FITC), anti-PD-1 (eFlour 605), anti-CD45RA (ECD)
anti-CCR7 (PE-Cy7), anti-CD27 (eFluor 780) and anti-CD160
clone BY55 (A647) from BD. Blocking assays used mouse
monoclonal anti-CD160 clone CL1-R2 (custom purified
from MBL International), mouse monoclonal anti-CD160
clone 688327, mouse monoclonal anti-HVEM clone 94801
and goat polyclonal anti-HVEM (R&D systems). PD-1
monoclonal antibody clone 5C4 (human IgG4 back-
ground) was obtained from sequence ID in patent applica-
tion US20090217401; binding specificity for PD-1 and
functional capacity of this antibody was characterized and
confirmed (data not shown).
Subjects
HIV-negative and HIV-1-infected subjects provided written
informed consent and studies were approved by the Royal
Victoria Hospital (Montreal, QC, Canada) and Boehringer-
Ingelheim Institutional Review Boards. The study popula-
tion of HIV subjects is shown in Table 1.
Primary cell preparation
PBMCs from subjects were obtained by leukapheresis
and isolated by density gradient centrifugation (Lymphocyte
Separation Medium; Wisent, St-Bruno, QC) and cryo-
preserved in 10% dimethyl sulfoxide (Hybri-Max DMSO;
Sigma-Aldrich, St Louis, MO); 90% Heat-Inactivated Fetal
Bovine Serum (HI-FBS) (PAA Laboratories, Etobicoke,
ON).
HLA typing
DNA for molecular HLA-typing was prepared from
whole blood using the QIAamp DNA blood kit (Qiagen
Inc., Mississauga, ON, Canada). Subjects were typed for
HLA class I antigen expression (A, B, and C alleles) by
sequence-based typing using kits from Atria Genetics





A-KBC-1035/M Chronic infection (No ART)* 02:02 29:02 15:03 58:02
B-RPJ-1038/M Chronic infection (No ART) 03:01 68:01 27:05 38:01
C-NF-1042/M Therapy failing 03:01 03:01 40:01 40:02
D-ST-1041/M Successfully Treated 68:01 68:01 53:01 58:02
*ART=Anti-retroviral therapy.interpret sequence information for allele typing (Conexio
Genetics, Perth, Australia).
Stimulation of primary CD4+ and Jurkat cells
Primary CD4+ T-cells were isolated from total PBMCs
by magnetic bead separation using EasySep CD4 nega-
tive selection kit (StemCell). Purity of isolated CD4+ cells
was consistently > 98%. Primary CD4+ cells were stimu-
lated with plate-bound anti-CD3 clone UCHT1 (BD) at
1 μg/ml and anti-CD28 clone CD28.2 (BD) at 0.5 μg/ml
and either human HVEM-mouse Fc fusion (R&D Sys-
tems) at a concentration of 0.2 μg/ml or its matched
mouse isotype control antibody. Jurkat T-cells were acti-
vated with Dynal beads (according to the supplier’s proto-
col, Pan Mouse IgG, Invitrogen) coated with anti-CD3
clone UCHT1 and anti-CD28 clone CD28.2 and either
anti-CD160 monoclonal antibody clone CL1-R2 (MBL
International), human HVEM-mouse Fc fusion, or their
matched isotype control mouse IgGs. Stimulation was per-
formed at a ratio of 4 beads/cell.
Tetanus toxoid stimulation assay
Total PBMCs from healthy donors were thawed in RPMI-
1640 medium containing 10% heat-inactivated human
serum (GemCell). Cells were washed twice with medium
and suspended at a final concentration of 1.5 × 106 cells/ml.
Tetanus toxoid (List Biological Laboratories) was added
at a concentration of 2.5 μg/ml. Blocking monoclonal
antibodies against CD160, custom-purified clone CL1-R2
(MBL International) and polyclonal HVEM antibodies
(R&D) or their matched isotype controls were used at
10 μg/ml. Cells were incubated for 5 to 7 days and then
IFNγ was measured in the supernatant by ELISA using
OptEIA Kit (BD) according to the supplier’s protocol.
Design of peptide-pool matrices and IFNγ ELISPOT assay
The HIV peptide sets used for the CFSE and IFNγ ELI-
SPOT assays were 15 amino acids (aa) with 11 aa overlaps.
The peptides were obtained from the NIH AIDS Research
and Reference Reagent Program (NARRRP, Rockville,
MD). Lyophilized peptides (n = 769) spanning all HIV-1
gene products were dissolved at a concentration of 10 mg/mL










02:10 06:02 2003 3.9 306 540
01:02 12:03 2003 2.25 289 961
02:02 03:04 2002 4.97 393 697
04:01 06:02 2000 <1.7 597 1377
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and 211 Env 15-mers corresponding to consensus clade B
sequence. Pools containing 1 to 16 peptides were prepared
and organized into matrices of Gag, Pol, Nef, Env and
accessory (Acc) gene peptide-pools such that each peptide
was present in two pools within each matrix. IFNγ secre-
tion by HIV-specific cells was quantified using the stand-
ard ELISPOT assay. Spots were counted with the CTL
ImmunoSpot 6 Analyzer (Immunospot, Cleveland, OH)
and results were expressed as spot forming cells per mil-
lion PBMCs (SFCs/106 PBMCs) following subtraction of
negative controls. The threshold for IFNγ ELISPOT posi-
tivity was set to a minimum of 50 SFC/106 PBMCs follow-
ing background subtraction with a minimum of 10 spots
and at least two fold over background values.
5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE)
dilution assay
Thawed PBMC were resuspended in PBS 1X and labeled
with 0.6 μM CFSE (Molecular Probes, Eugene, Oregon).
CFSE labeled PBMCs were stimulated with 2 μg/mL of
HIV consensus B peptides identified in the ELISPOT assay;
Gag7876 (EKIRLRPGGKKKYKL) for subjects NF-1042
and KBC-1035, Gag937 (IYKRWIILGLNKIVR) for subject
RJP-1038 and Pol5683 (TAVQMAVFIHNFKRK) for sub-
ject ST-1041, in RPMI-1640 containing 10% human AB
serum (Gemini, Burlington, ON). Stimulation with media
alone served as a negative control, whereas stimulation with
25 ng/ml of Staphylococcol enterotoxin B (SEB) (Sigma-
Aldrich) and 2 μg/mL of CEFT (CMV, EBV, Influenza and
Tetanus peptides) were used as positive control stimula-
tions. Monoclonal antibodies directed against immune
checkpoint molecules (PD-1, CD160 or HVEM) along
with their corresponding isotype controls were added to
the culture conditions at 5 μg/mL. All stimulatory condi-
tions were tested in quadruplicates. Following six days of
incubation at 37°C and 5% CO2, cells were monitored for
viability with the Trypan blue exclusion test and further
stained for cell surface markers using Live/Dead (Molecu-
lar Probes), αCD3, αCD8 (ebioscience), and αCD4 mAbs
(BD Biosciences, Mississauga, ON). PBMCs were acquired
using a BD LSRII flow cytometer and analyzed with
FlowJo software version 9.4.11 (FlowJo LLC, Ashland,
Oregon).
Statistical analysis
Statistical analysis and graphical presentation was per-
formed using GraphPad Prism 4 (GraphPad software, San
Diego, CA), FlowJo 9.1 (Treestar) and FACSDiva V6 (BD
Biosciences). Two-tailed paired t test was used to assess
differences in the relative frequency of CD4+CD160+
T-cells before and after TCR stimulation from the same
donors and in the IL-2 production following triggering
with HVEM-Fc. The non-parametric Kruskal-Wallis andDunn’s tests were used to analyze data on the enhance-
ment of T cell activation as shown in Figure legends.
Results
Expression of CD160 isoforms on primary T-cells and
binding to HVEM
One aim of this study was to develop screening assays to
evaluate the impact of CD160 antibodies on the enhance-
ment of HIV-specific CD8 T-cell responses. CD160 was
previously reported to mediate a co-stimulatory role on
CD8+ T-cell activation upon binding to MHC-I, or a co-
inhibitory role on CD4+ T-cell activation upon binding to
HVEM. Our first aim was to establish an inhibitory assay
to test anti-CD160 antibody candidates with potential
blocking capacity on T-cell activation, herein CD4+ T-cells.
To this end, we assessed the expression of CD160 on CD4+
T-cells before and after TCR activation to select the optimal
time point for CD160 triggering. Levels of CD160 surface
expression were determined using the BY55 clone of anti-
CD160 that preferentially recognizes the GPI isoform [18].
Consistent with earlier reports [23], we observed that
CD160 was expressed on a small fraction (2-8%) of ex vivo
CD4+ T-cells at baseline (Figure 1A & B). CD160 expres-
sion on cells stimulated with anti-CD3 and anti-CD28
monoclonal antibodies was higher at 48 h post-stimulation
(p = 0.03) compared to the ex vivo baseline levels. Notably,
T-cells which remained un-stimulated for 48 hr showed the
highest levels of CD160 compared to TCR-stimulated
and ex vivo stained cells from matching individual donors
(n = 3, p = 0.005 and p = 0.001, respectively) (Figure 1A,
middle and right panels). Similar results were also obtained
with CD8+ T-cells (data not shown). The up-regulation of
CD160 on resting cells ex vivo and its down-regulation
following TCR stimulation thus contrasted observations
by Cai et al. [23] who showed that CD160 is upregulated
on CD4 T-cells following TCR stimulation. Therefore, we
assessed whether this discrepancy was attributable to the
expression of the newly identified isoform of CD160, the
full-length trans-membrane isoforme (CD160-TM). The
CD160-TM isoform is induced on NK cells upon stimula-
tion with a panel of cytokines including IL-2, IL-12, IL-15
and IL-18 [18]. Our data in Figure 1C showed that the
CD160-TM isoform was indeed clearly detectable at the
transcriptional level in CD4+ T-cells as measured by quan-
titative RT-PCR. However, following TCR stimulation,
both CD160-TM and CD160-GPI transcripts decreased
gradually with time and became undetectable by 72–96 h
post-TCR stimulation. Of note, we could not confirm the
specific expression of CD160-TM at the protein level due
to the lack of specific antibodies capable of distinguishing
between the two isoforms (note that CD160-GPI anti-
bodies poorly recognize the CD160-TM isoform [18]).
HVEM expressed on the surface of antigen presenting
cells was previously shown to bind CD160-GPI on CD4+
Figure 1 Expression of CD160 isoforms in primary CD4+ T-cells and binding to HVEM. A) Left panel: Representative FACS analysis of
CD160 on primary CD4+ T-cells isolated from total PBMCs of a healthy donor (ex vivo at baseline), gated on CD3+CD4+CD8− cells. Middle panels:
CD160 surface expression following 48 h of resting (non-stimulated, NS) or TCR activation (plate-bound anti-CD3 and soluble anti-CD28). Right panel:
overlapping histograms showing CD160 surface expression from TCR-stimulated CD4+ T-cells (dotted empty histogram) in comparison to 48 h rested
CD4 (filled grey histogram) and freshly isolated CD4 cells (filled black histograms) all from the same individual donor. B) Frequency of CD160
+CD4+ double positive population following 48 h of resting or TCR stimulation compared to freshly isolated (ex vivo) cells (n = 3). C) Kinetics of
CD160-GPI and CD160-TM isoform expression at the mRNA level by quantitative RT-PCR in primary CD4+ T-cells (cells from n = 3 independent
healthy donors) stimulated through TCR for 4 days. Values are relative to the house-keeping GAPDH gene transcripts (n = 3). HeLa cells were
used as a negative control for CD160 TM transcription. D) Binding of HVEM to the two isoforms CD160. Left panel: Schematic representation
for the TRF binding assay between CD160 (over-expressed by CHO-K1 cells) and the soluble ligand HVEM containing the human Fc1 (detection
with anti-human Fc1). Right panel: Measuring the signal/background (S/B) for HVEM binding to both CD160-GPI and CD160-TM cells by the
TRF assay under decreasing concentrations of HVEM-Fc.
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to study the details of HVEM binding to CD160 and
examine its binding to the newly identified isoform of
CD160-TM, we established CHO-K1 cell lines that over-
expressed either CD160-GPI or CD160-TM to assess the
binding of soluble HVEM-Fc. The assay was based on
the highly sensitive dissociation-enhanced lanthanide fluor-
escent immunoassay” (DELFIA; Perkin Elmer) with time-
resolved fluorescence (Figure 1D, left panel). HVEM-Fc
specifically but differentially bound to the CD160-GPI and
CD160-TM isoforms with a signal to background ratio
(S/B) of 11 and 3, respectively (Figure 1D, right panel).
Together, CD160-TM, similar to CD160-GPI, was expressed
by T-cells and recognized by HVEM, albeit with a lower
level of binding compared to CD160-GPI. However, this
lower level of binding could be due in part to a lower sur-
face expression of CD160-TM.
Antibody-mediated specific blockade of CD160/HVEM
binding
We next screened benchmark antibodies directed against
CD160 and HVEM to evaluate their potential capacity to
block CD160/HVEM interaction and to select candidates
for functional rescue of antigen-specific T-cells. Previous
studies have shown that binding of HVEM to CD160 can
be inhibited by the CD160 monoclonal antibody (mAb)
CL1-R2 [30], an antibody with antiangiogenic activity [31].
We used the TRF CD160/HVEM binding assay to confirm
these observations and to further evaluate other CD160
and HVEM antibodies (some of which were previously
shown to enhance HIV-specific responses, [14]). The
TRF assay consisted of a fixed concentration of soluble
HVEM-Fc (1 μg/ml) and serial dilutions of either CD160
mAbs (clones CL1-R2 and clone 688327) or HVEM poly-
clonal and monoclonal (clone 94801) Abs. CD160 Abs
readily inhibited the binding of HVEM to either CD160-
GPI or CD160-TM isoforms (Figure 2A) in the TRF assay.
In contrast, the polyclonal HVEM antibody, which inhib-
ited the binding of HVEM to CD160-GPI, enhanced
HVEM binding to CD160-TM. Furthermore, the mono-
clonal HVEM Ab (clone 94801) enhanced the binding of
HVEM to both CD160 isoforms (Figure 2B). Together,
these results showed that CD160 or HVEM antibodies
had differential capacities to inhibit (or augment) the
interaction between HVEM and specific CD160 isoforms.
Triggering of CD160-GPI is consistent with positive
regulation of CD4+ T-cells
An inhibitory assay with primary CD4+ T-cells was estab-
lished whereby TCR and CD160 were simultaneously trig-
gered in the presence or absence of specific antibodies to
either HVEM or CD160 (CL1-R2 clone). CD4+ T-cells
were isolated from total PBMCs of healthy donors and
rested overnight to up-regulate CD160 as described earlier(expression was monitored by flow cytometry). As shown
in Figure 3A (left and right panels), addition of HVEM-Fc
significantly reduced IL-2 production from CD4+ T-cells
that were stimulated with anti-CD3 and anti-CD28 anti-
bodies for 24 h. Blockade of HVEM with specific anti-
HVEM monoclonal Ab (Figure 3A left panel) partially
restored IL-2 production from cells triggered with TCR/
HVEM-Fc compared to treatment with matched isotype
control Ab (p = 0.007). Similarly, treatment of TCR/
HVEM-Fc triggered cells with CD160 specific monoclo-
nal antibodies increased IL-2 production to reach levels
equal to or higher than cells stimulated with TCR alone
(Figure 3A right panel) (p = 0.006). Interestingly, IL-2
production by TCR-stimulated cells in the absence of
the HVEM-Fc ligand was also enhanced by the CD160
mAb (p = 0.04). Meanwhile CD160 antibody had no im-
pact on CD4+ T-cell activation in the absence of TCR
stimulation, thus suggesting that the CD160 antibody-
mediated enhancement of cell activation is TCR-dependent.
These results are consistent with earlier reports showing
that targeting CD160 with monoclonal antibodies may en-
hance TCR-mediated signaling in T-cells [32,33].
As we showed earlier, CD160 is expressed in at least two
different isoforms on both CD4+ and CD8+ T-cells. To
further gain insight into the functional roles of these two
isoforms, we selectively and exclusively over-expressed
cDNA clones of the alternatively spliced CD160-GPI or
CD160-TM in Jurkat T-cell lines that also encode an
NFAT-responsive luciferase reporter gene (Jurkat-NFAT-
Luc) and assessed the functional impact of CD160 trigger-
ing by HVEM ligand and cognate mAbs. Figure 3B (left
panel) shows FACS data for the different cellular clones
that apparently represent high levels for CD160-GPI ex-
pression (up to 100%) and intermediate levels (up to 30%)
for CD160-TM. The intermediate levels of CD160-TM de-
tected by FACS reflects the difference of the CD160 BY55
monoclonal antibody, used in current phenotyping assays,
in binding to the CD160-TM isoform relative to the
CD160-GPI isoform [18]. To ensure similar levels of ec-
topic expression of the individual isoforms in the respect-
ive cell lines and to also confirm the absence of intrinsic
CD160 expression, we quantified the CD160-GPI and
CD160-TM mRNA transcripts ectopically expressed in
each of these cell lines. Data presented in Figure 3B
(right panel) showed that no intrinsic CD160 expression
was detected in the non-transfected control Jurkat-NFAT-
Luc cells. In contrast, Jurkat cells transfected with CD160-
TM only expressed the full-length TM isoform transcripts
whereas the Jurkat cells transfected with the CD160-GPI
plasmid expressed the GPI transcripts. Two sets of Taq-
man probes were used in these studies and one set was
not selective and hybridized both the short CD160-GPI
and the full-length CD160-TM in the two respective cell
lines and demonstrated similar RNA expression levels.
Figure 2 Differential inhibition of HVEM/CD160 binding with benchmark tool antibodies. TRF assay measuring the potency of different
antibodies to inhibit the binding of recombinant human HVEM-Fc chimera to CD160+ CHO-K1 cells. A) CD160 monoclonal antibodies inhibit
binding of HVEM-Fc to both CD160-GPI and CD160-TM isoforms. B) Polyclonal HVEM (left panel) and monoclonal HVEM (right panel) antibodies
both enhance binding of HVEM-Fc to CD160-TM isoform. The polyclonal anti-HVEM inhibits HVEM-Fc binding to CD160-GPI (left panel). Antibody
concentrations are plotted on the X axis whereas, the calculated percentage of inhibition of binding is plotted on the Y axis. Matched isotype
control antibody for each individual antibody candidate was also used in the assay (empty circles and squares). CTL = control, mAb =monoclonal
antibody, pAb = polyclonal antibody.
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and confirmed the exclusive expression of the different
CD160 isoforms in these two cell lines (Figure 3B right
panels).
The effect of HVEM-mediated CD160 triggering on TCR
activation was assessed by measuring the NFAT-responsive
luciferase activity of Jurkat cells expressing either CD160-
GPI or CD160-TM isoforms. Dynal Beads coated with anti-
CD3, anti-CD28 and either HVEM-Fc or matched isotype
control were used to perform these experiments. HVEM-Fc
specifically activated Jurkat cells that expressed CD160-GPI, but not the TM isoform (Figure 3C, left 3 panels). Of
note, enhancement of cell activation by HVEM-mediated
CD160-GPI triggering was observed only when lower con-
centrations of anti-CD3 antibodies were loaded to the ac-
tivator beads (Additional file 1A). To further ensure equal
loading capacity for stimulating antibodies and ligands, ac-
tivator beads were stained with secondary anti-mouse
antibody and analyzed by FACS (Additional file 1B).
Similar to HVEM-Fc-mediated CD160-GPI triggering,
TCR co-stimulation with the CD160 monoclonal anti-
body CL1-R2 enhanced activation of Jurkat-CD160-GPI,
Figure 3 Triggering of CD160-GPI is consistent with a positive co-stimulation role. A) Triggering of primary CD4+ T-cells with either plate-bound
anti-CD3 (1 μg/ml) and anti-CD28 (0.5 μg/ml) or anti-CD3, anti-CD28 and HVEM-Fc (0.2 μg/ml) in the presence or absence of either anti-HVEM (left panel)
or anti-CD160 clone CL1-R2 (right panel). IL-2 was measured in the supernatant by ELISA at 24 h post stimulation. Iso-IgG represents the matched isotype
control antibody. P values were determined by two-tailed paired t test (data from three independent healthy donors). B) Left panels: Surface expression
of CD160-GPI and CD160-TM on Jurkat-NFAT-Luc cells stably-transfected with CD160 plasmids. Mock-transfected cells (light grey histograms in middle
and right panels) were used to set the positive and negative gates for FACS. CD160-TM is weakly detected with CD160-GPI antibodies (BY55 clone).
Right panels: Quantitative RT-PCR for CD160-GPI and CD160-TM isoforms in Jurkat cells over-expressing either CD160-GPI or CD160-TM, values are
relative to the house-keeping GAPDH gene transcripts (One representative experiment, n = 2). Non-transfected Jurkat (control cells) and HeLa cells were
used as additional negative controls for CD160 expression. The left graph represents results with a set of Taqman probes that were not isoform selective
and hybrdize both CD160-GPI and CD160-TM to demonstrate similar RNA expression levels, whereas the right graph used a set of probes that were
CD160-TM specific to confirm the exclusive expression of the different CD160 isoforms in the two cell lines. C) Simultaneous triggering of TCR and CD160
using magnetic Dynal beads coated with anti-CD3, anti-CD28 and either HVEM-Fc (left panels), CD160 monoclonal antibodies (right panels) or their matched
IgGs. Cell activation was monitored by measuring the absolute luciferase counts. Control cells are original Jurkat-NFAT-Luc cells non-transfected with
either of the CD160 isoforms. NS: non-stimulated. P values were calculated by non-parametric two-tail t test (Mann–Whitney).
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Identical results were also obtained with anti-CD160
clone 688327 (data not shown).
Altogether, the engagement of CD160-GPI, but not
CD160-TM, by either HVEM-Fc or specific mAb en-
hanced the Jurkat T-cell activation as measured by the
higher NFAT-responsive luciferase activity. The lack of
any significant impact of HVEM-Fc on the CD160-TM
isoform together with the positive co-stimulation medi-
ated by HVEM-Fc triggering of CD160-GPI in the Jurkat
assay suggested that the HVEM-Fc mediated inhibition
of IL-2 production that we observed with primary CD4+
T-cells (Figure 3A) is likely mediated by HVEM inter-
action with BTLA, which is constitutively expressed on
CD4+ T-cells (data not shown and [34]).CD160 and HVEM antibodies specifically enhance CD4+
T-cell responses to a recall antigen
As a first line high throughput assay capable of identify-
ing antibodies that modulate antigen specific T-cell acti-
vation, we analyzed memory T-cell responses to Tetanus
toxoid (TT) recall antigen. This assay allowed us to
compare the potency of anti-CD160 (CL1-R2) mAb and
the polyclonal anti-HVEM antibodies to enhance T-cell
response. Both antibodies increased the production of
IFNγ by PBMCs from healthy responders upon stimula-
tion with suboptimal concentrations of TT (2.5 μg/ml)
in a 5-day culture assay (Figure 4A). No IFNγ produc-
tion was observed in the absence of antigenic stimula-
tion (data not shown).
Tetanus toxoid is known to elicit a CD4+ T-cell response
[35]. In order to confirm the assay specificity, we tested the
CD4 response by monitoring the frequency of TT-specific
CD4+ T-cells as determined by the surface expression of
IL-2Rα (CD25) and OX40 (CD134). This method was pre-
viously shown to identify Ag-specific CD4+ T-cells without
the need for HLA class II multimers [35]. Analogous to the
experimental conditions described above, PBMCs from
healthy responders were stimulated with the Tetanus anti-
gen (TT) for 5 days in the presence or absence of anti-
CD160 antibodies. As shown in Figure 4B, only CD4+
T-cells responded to TT-stimulation by up-regulating
both CD25 and CD134 [the frequency of CD25+CD134+
DP cells increased from an average of 0.3% to 1.7% (n = 5)].
In contrast, no significant impact was observed on the
CD8+ T-cell population. Interestingly, addition of CD160
mAb increased the frequency of CD25+CD134+ DP frac-
tion to an average of 3.8% (n = 5), whereas no change in
frequency was observed with isotype control antibodies.
These results showed that CD160 and HVEM antibodies
specifically enhanced memory CD4+ T-cell responses
(both qualitatively and quantitatively) against a recall anti-
gen upon re-stimulation.Combined targeting of CD160 and PD-1 enhances
HIV-specific CD8+ T-cell proliferation
The impact of targeting CD160, with CD160-specific anti-
bodies on HIV antigen-specific exhausted T-cells from
HIV-infected subjects was studied ex vivo to evaluate its
therapeutic potential. We first comprehensively screened
HIV-1 epitopes by IFNγ ELISPOT to map the different
T-cell responses to HIV-1 peptides from infected subjects.
The primary objective of this comprehensive analysis was
to determine the baseline responses to HIV-1 peptide
stimulations from subjects with different categories/stages
of disease and in turn to characterize the change in re-
sponses upon targeting CD160 and/or other key cell sur-
face regulators, herein PD-1. Study samples were obtained
from both cART-treated aviremic and cART-naïve viremic
subjects, with one of four subjects having the protective
HLA allele B27 (Table 1). As shown in Additional file 2,
the breadth of ex vivo responses was higher in samples
from the viremic subjects compared to samples from the
successfully treated one. Samples from the HLA-B27 sub-
ject displayed the highest response values.
Since CD160+PD-1+ double positive (DP) populations of
HIV-1-specific CD8+ T-cells were previously shown to
represent a highly exhausted cell subset [14], we measured
the co-expression of CD160 and PD-1 on both total and
selected antigen-specific cells based on the CD8+ T-cell
epitopes defined by the IFNγ ELISPOT assay. As shown in
Figure 5A, although the frequency of this DP population
on total CD8+ T-cells was modest, the DP frequency was
higher in CD8+ T-cells from HIV viremic subjects relative
to the cART treated and virus-suppressed subject or
healthy donors (Left panel). Most notably, the DP popula-
tion comprised a relatively high proportion (3-45%, de-
pending on the multimer used) of the HIV-specific CD8+
T-cells in the viremic subjects when compared to the
A*02 CMV Ag-specific population from a HIV-uninfected
donor (Figure 5A, right panel).
We further compared the effect of dual targeting of
CD160 and PD-1 versus the dual targeting of HVEM
and PD-1 [14] (at concentrations of 5 μg/ml for each in-
dividual antibody) on the functional restoration of HIV-
specific CD8+ T-cell responses. The combination of CD160
and PD-1 specific Abs increased the frequency of proliferat-
ing HIV-specific CD8+ T-cells by 4.3- and 3.2-fold in sam-
ples from subjects NF-1042 and KBC-1035, respectively
(Figure 5B, left and right panels, p = 0.04 for both). This
was comparable to a combination of HVEM and PD-1
Abs that resulted in a 3.8- and 3-fold increase in HIV-
specific CD8+ T-cell proliferation from these respective
subjects (p = 0.03 for both). Lower levels of enhancement
were observed when these antibodies were used individu-
ally, and these results are consistent with earlier observa-
tions in the LCMV mouse model that show enhancement
of Ag-specific cell functions with anti-LAG-3 only upon
Figure 4 (See legend on next page.)
El-Far et al. Journal of Translational Medicine 2014, 12:217 Page 11 of 16
http://www.translational-medicine.com/content/12/1/217
(See figure on previous page.)
Figure 4 CD160 and HVEM antibodies specifically enhance IFNγ production by CD4 T-cells in response to the Tetanus toxoid recall
antigen. A) IFNγ production by total PBMCs (1.5 × 106 cells/ml) stimulated with 2.5 μg/ml of Tetanus toxoid in the presence or absence of
anti-CD160 clone CL1-R2 mAb (left panel), HVEM pAb (right panel) or their matched isotype control Abs (n = 10). IFNγ was measured by ELISA
from the supernatant following 5 days of stimulation. B) Left panel: Surface staining of cells using anti-CD3, anti-CD4, anti-CD8, anti-CD25 and
anti-CD134 (OX40) analyzed by FACS (gating on CD3+ lymphocytes followed by gating on either CD4+ or CD8+ T-cells). Right Panel: analysis of
the frequency of CD25+CD134+ double positive CD4+ and CD8+ T-cell populations (n = 5). P values were determined using the nonparametric
Kruskal-Wallis and Dunn’s post-test.
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not observe any significant enhancement of CD4+ T-cell
proliferation in response to the p24 antigen in the pres-
ence of these antibodies (data not shown), which suggests
that the observed functional enhancement was specific to
CD8+ T-cells. Co-targeting of PD-1 with either CD160 or
HVEM showed very low levels of enhancement when
peptide pools specific to other infectious agents (CEFT:
CMV, EBV, Influenza and Tetanus) were used as controls
(Additional file 3A & B). Of note, no significant enhance-
ment was obtained with the CD160 and PD-1 combined
antibody treatment in samples from subjects with low
viral load (ST-1041 and RJP-1038), whereas HVEM spe-
cific antibodies diminished the frequency of proliferating
cells (compared to stimulation in the absence of antibody
candidates) in these samples (Figure 5c). No activation-
induced cell death (AICD) was observed with HVEM
antibodies (data not shown).
Discussion
CD160 belongs to the broad family of T-cell co-regulators.
In our efforts to generate a screening assay for selecting
antibody candidates with the capacity to block HVEM
binding to CD160 and to functionally impact T-cell activa-
tion, we over-expressed the two known isoforms of
CD160 (GPI and TM) in Jurkat cells harboring a luciferase
reporter gene. HVEM ligand enhanced TCR-mediated ac-
tivation only in cells expressing the CD160-GPI isoform
and not the CD160-TM isoform. The lack of HVEM-
mediated activation of CD160-TM may, in part, be due to
the weak interaction between these proteins as suggested
by our binding assays. However, as we could not confirm
equal surface expression of CD160-TM, compared to
CD160-GPI, due to the lack of CD160-TM specific
antibodies, we cannot exclude the possibility that the
low binding of HVEM-Fc to the CD160-TM expressing
cells is due, at least in part, to a lower CD160-TM expres-
sion at the cell surface. Yet, similar levels of transcription
were observed for both CD160-GPI and CD160-TM iso-
forms in the CHO-K1 cells, used for the binding assays,
and in Jurkat cells, used for the functional assays. Further-
more, monoclonal and polyclonal antibodies to HVEM
enhanced the binding of HVEM-Fc to the CD160-TM in
the CHO-K1 cells, which suggests that CD160-TM was
expressed to significant levels at the cell surface. Similar toantibody-mediated enhancement of HVEM-Fc binding to
CD160, earlier observations were also reported for the
binding of CD160 to MHC class I molecules [19]. The
anti-MHC I monomorphic antibody W6/32 mAb en-
hanced interaction between cells expressing CD160 and
cells expressing the class I molecules suggesting that lig-
and multimerization may promote binding to CD160-
TM (20). However, multimerization of HVEM may not
be the only possible mechanism to induce HVEM binding
to CD160-TM as potential antibody-mediated changes in
the HVEM protein conformation may also play a role The
distinction between CD160-GPI and CD160-TM with re-
gard to the need for HVEM multimerization or antibody-
mediated conformational change might explain the lack of
HVEM-mediated effect on Jurkat-CD160-TM with bead-
bound monomeric HVEM-Fc fusion. How the MHC I or
HVEM ligands localize/multimerize or change their con-
formational structure under physiological conditions in
order to promote binding to CD160, requires further in-
vestigations. HVEM is expressed as a monomer and upon
binding to the homotrimeric LIGHT forms a trimeric
multimer [36,37]. Gonzalez et al. [37] suggest that BTLA
is likely to bind to HVEM in the presence of LIGHT or
LTα, whereby these latter receptors favor the formation of
a trimeric HVEM. The regulation of HVEM association
with CD160-TM through multimerization or conform-
ational change and its impact on T-cell activation remains
to be elucidated.
Triggering of CD160-GPI isoform over-expressed by
the CD4+ Jurkat T-cell line with monoclonal antibodies in
our study was consistent with a positive co-stimulatory
role. Similarly, CD160 stimulation was previously shown
to enhance CD3-induced activation and proliferation of
peripheral blood CD160+ T cells [33] and also CD4+CD160+
T cells isolated from inflammatory skin lesions [32]. Though
these results are in accordance with earlier reports that used
the anti-CD160 CL1-R2 (IgG1) or the BY55 (IgM) [33]
clones, they contrast with recent work by Cai et al.,
[23] showing that triggering of CD160 on primary CD4+
T-cells with the CD160 monoclonal antibody 5D.10A11
inhibits cell activation and cytokine production. These ap-
parently discordant observations suggest that CD160 may
differentially regulate either activating or inhibitory signal-
ing pathways, which may depend on the type/clone of
antibody or cognate ligand used to engage the target.
Figure 5 (See legend on next page.)
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Figure 5 Enhanced CD8+ T-cell proliferation to antibody-mediated blockade of PD-1 in combination with either CD160 or HVEM
antibodies. A) Histogram summarizing the phenotypic analysis showing the frequencies of CD160+PD-1+ double positive population on total
CD8 (left panel: each dot represents an independent staining from the same subject) and HIV-specific (right panel) T-cells from the four
recruited study subjects. L933 represents the HIV-uninfected donor used as a control. HIV pentamers from each subject is annotated above each
bar (right panel). Gating was done on CD3+ lymphocytes followed by gating on either total CD8+ T-cells or pentamer HIV-specific CD8+ T-cells.
Note that we were unable to fold the peptides identified in the ELISPOT assay with HLA-restricted multimers from cART-treated subject. B) CFSE
lymphoproliferation assays on total PBMCs from the viremic subjects NF-1042 and KBC-1035 gated on CD3+CD4−CD8+ T-cells. PBMCs stimulated
or not with Gag7876 (restricted by HLA-B*1501 for KBC-1035, and HLA-A*0301 for NF-1042) in the absence or presence of blocking antibodies
(4 replicates for each condition). C) PBMCs from ST-1041 and RJP-1038 stimulated or not with Pol5683 (restricted by HLA-A*11, A*03, A*68) and
Gag7937, restricted by HLA-B*2705, respectively (4 replicates for each condition). P values were determined using the nonparametric Kruskal-Wallis
and Dunn’s post-test.
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(GPI and TM) in CD4+ and CD8+ T-cells with a pos-
sible differential expression and regulation of ligand
binding may also account for the divergent reports on
CD160 functions as the selectivity of 5D.10A11 anti-
body [23] for the various CD160 isoforms and the
resulting effect on TCR signaling have not been char-
acterized. Of note, in our Jurkat-NFAT-Luciferase
assay with CD160-TM expressing cells, HVEM-Fc did
not elicit either a negative or positive effect and may
reflect a requirement for HVEM multimerization or in-
duced conformational changes to promote CD160-TM
binding.
Our study also showed that the GPI isoform was up-
regulated on rested T-cells (both CD4+ and CD8+) ex vivo
likely due to the culture conditions. This apparent up-
regulation of CD160 on resting cells and the contribution
of ex vivo culture conditions such as the use of human
serum require more investigation. Yet CD160 was down-
regulated by TCR activation, which indicates that expres-
sion of CD160 on primary T-cells is more complex than
initially thought. CD160-GPI is likely to undergo receptor
shedding upon T-cell stimulation similar to the previously
described mechanism for CD160 on NK cells stimulated
with IL-15 [38]. Although CD160-GPI and CD160-TM
share the same extracellular domains, the GPI isoform
does not contain a transmembrane domain. The two iso-
forms have differential binding characteristics for CD160
antibodies [18] and they may also differ in their signaling
capacity. The presence of these two isoforms of CD160
and their potential differential expression in T-cells re-
quires further studies, particularly in the context of im-
mune exhaustion. Indeed, our results showed that HVEM
antibodies function differently in ex vivo T-cell assays on
samples isolated from HIV-infected subjects with higher
viral loads compared to aviremic subjects. These anti-
bodies restore HIV-specific CD8+ T-cell proliferation in
lymphocytes isolated from viremic subjects, but in con-
trast dampen the response in CD8+ T-cells from aviremic
subjects. This difference may be related to potential differ-
ential expression of the CD160 isoforms in viremic and
aviremic subjects, meanwhile assuming that CD160-TMmediates a negative regulatory role in this context. An-
other potential setting could also be that the anti-HVEM
antibodies may enhance binding of HVEM to the negative
regulator BTLA that might be differentially expressed in
aviremic versus viremic subjects. However these different
regulatory mechanisms need more investigations.
Our functional analyses suggest that a pharmacologic
effect in HIV viremic subjects may be elicited through
the co-targeting of both CD160 (through Ab-mediated
activation) and PD-1 (through Ab-mediated blockade).
In one notable instance where the CD160+PD-1+ DP
HIV-specific CD8+ T-cell subset was significantly higher
in the HLA-B*2705 chronic infected subject compared
to the HIV-uninfected control, the combined targeting
of CD160 and PD-1 did not enhance response to HIV
antigens. However, this subject had the largest breadth
and magnitude of response to HIV peptides in agree-
ment with earlier reports associating the HLA-B*2705
allele with protection from disease progression in HIV
[39,40] and virus clearance in HCV [41]. In contrast to
the B*2705 subject, the successfully treated subject
showed low frequencies of the CD160+PD-1+ DP HIV-
specific CD8+ T-cell, which is likely associated with low
levels of viremia (less than 40 RNA copies/ml) and con-
sequently reduced immune activation [14]. Similar to
the B*2705 subject, combined targeting of CD160 and
PD-1 in the successfully treated subject did not enhance
HIV-specific T-cell proliferation and surprisingly, HVEM
antibodies decreased cell proliferation likely by enhancing
binding of HVEM to CD160-TM or BTLA [28,29]. This
finding shows that functional T-cells may lose their cap-
acity to proliferate and suggest that chronicity of infection
and viral load levels may be used as predictive markers to
identify patients who may benefit from immunotherapeu-
tic intervention that target immune checkpoint molecules.
Conclusions
In this study we used in vitro and ex vivo cellular assays
to evaluate the targeting of CD160, relative to HVEM, as
a co-target with PD-1 in immunopotentiating a response
to HIV infection. Antibodies against CD160 and PD-1,
used in combination, significantly enhanced HIV-specific
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from viremic subjects but showed no impact on CD8+
T-cell response from aviremic subjects. Therapeutic immu-
nopotentiation through the specific targeting of negative
and positive immune regulators on T-cells represents an
interesting approach to complement current treatment
regimens in HIV infection. To further our understanding
on the HVEM/BTLA/LIGHT/CD160 network during dis-
ease, and to identify new correlates or predictive bio-
markers in patients who may benefit from the combined
Ab treatment with other targets, it would be interesting to
analyze the differential expression of these molecules, in-
cluding the two isoforms of CD160, in a longitudinal study
that spans acute, chronic and treatment phases.Additional files
Additional file 1: Stimulation of Jurkat-CD160-GPI with decreasing
concentrations of anti-CD3 in the presence or absence of HVEM-Fc.
A) Dynal Beads (4 × 107 beads) were loaded with 80, 40, 20 or 10 ng of
anti-CD3, a fixed concentration of anti-CD28 (1 μg) and 3.2 μg of either
HVEM-Fc or the Isotype control antibody IgG2a. Stimulation was
performed for 24 h at a ratio of 4 beads/cell. P values were calculated by
non-parametric two-tail t test (Mann–Whitney). B) A representative
Loading control for activator beads (set #4: 10 ng of anti-CD3) monitored
by FACS. Beads loaded with anti-CD3, anti-CD28 and either HVEM-Fc or
Isotype control were stained with the secondary antibody Goat anti-mouse
(GAM-FITC).
Additional file 2: Breadth of responses to HIV-1 clade B consensus
peptides measured by IFNγ ELISPOT assay. Absolute numbers of
recognized peptides to HIV-1, calculated as the sum of all responses
to peptides from the same protein. Responses are derived from four
HIV-1 infected subjects described in Table 1. A larger breadth was
observed in the B*027-expressing subject.
Additional file 3: CFSE lymphoproliferation assays on total PBMCs
from the four subjects stimulated with the control peptide pools
CEFT (4 replicates for each condition). P values were generated using
the nonparametric Kruskal-Wallis and Dunn’s post-test. * Represents a
significant p value <0.05.Competing interests
All authors were employees of Boehringer Ingelheim Canada when this work
was performed.
Authors’ contributions
ME designed the study, performed the experiments, analyzed the data and
wrote the manuscript. CP, LP, PS and EW helped with the Jurkat assays and
RNA quantification. YP, helped with the CFSE assays and writing of the
methods section. J-FF, ILR, RCB and MGC helped with data interpretation
and study design. GK designed the study, analyzed the data, supervised the
work and wrote the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We would like to thank Dr. Gordon J. Freeman (Dana Farber Cancer Institute,
USA) for fruitful discussions and comments on the data presented in the
manuscript. Thanks to Dr. Jean-Pierre Routy (Royal Victoria Hopspital, Canada)
for discussions and recruitment of HIV subjects. We would like also to thank
Kishanda Vyboh for careful reading of the manuscript.
Funding
This work was supported by Boehringer Ingelheim Canada.Author details
1Boehringer Ingelheim Ltd., 2100 Rue Cunard, Laval, Quebec, Canada.
2Caprion/ImmuneCarta Services, Montreal, Québec, Canada. 3Centre de
Recherche du CHUM, Montreal, Quebec H2X 0A9, Canada. 4Boehringer
Ingelheim (Canada) Ltd., 5180 South Service Road, Burlington, Ontario L7L
5H4, Canada.
Received: 6 May 2014 Accepted: 21 July 2014
References
1. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ: The function of
programmed cell death 1 and its ligands in regulating autoimmunity
and infection. Nat Immunol 2007, 8:239–245.
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in
tolerance and immunity. Annu Rev Immunol 2008, 26:677–704.
3. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH:
Loss of CTLA-4 leads to massive lymphoproliferation and fatal
multiorgan tissue destruction, revealing a critical negative regulatory
role of CTLA-4. Immunity 1995, 3:541–547.
4. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G,
Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I,
Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance
HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J,
Motzo C, Cucca F, Hess JF, et al: Association of the T-cell regulatory gene
CTLA4 with susceptibility to autoimmune disease. Nature 2003,
423:506–511.
5. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman
GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic
viral infection. Nature 2006, 439:682–687.
6. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B,
Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK,
Sekaly RP: Upregulation of PD-1 expression on HIV-specific CD8+ T cells
leads to reversible immune dysfunction. Nat Med 2006, 12:1198–1202.
7. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey
EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B,
Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P,
Ahmed R, Freeman GJ, Walker BD: PD-1 expression on HIV-specific T cells
is associated with T-cell exhaustion and disease progression. Nature
2006, 443:350–354.
8. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T,
Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le
Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ,
Rosenberg ES, Walker BD: Upregulation of CTLA-4 by HIV-specific CD4+ T
cells correlates with disease progression and defines a reversible
immune dysfunction. Nat Immunol 2007, 8:1246–1254.
9. El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, Janbazian L, Fonseca
S, van Grevenynghe J, Yassine-Diab B, Sekaly RP, Haddad EK: T-cell
exhaustion in HIV infection. Curr HIV/AIDS Rep 2008, 5:13–19.
10. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD,
Ahmed R: Viral immune evasion due to persistence of activated T cells
without effector function. J Exp Med 1998, 188:2205–2213.
11. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R: Viral
persistence alters CD8 T-cell immunodominance and tissue distribution
and results in distinct stages of functional impairment. J Virol 2003,
77:4911–4927.
12. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH,
Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR: Enhancing
SIV-specific immunity in vivo by PD-1 blockade. Nature 2009,
458:206–210.
13. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR,
Freeman GJ, Vignali DA, Wherry EJ: Coregulation of CD8+ T cell
exhaustion by multiple inhibitory receptors during chronic viral
infection. Nat Immunol 2009, 10:29–37.
14. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, Filali-Mouhim A,
Loubert JB, El-Far M, Dupuy FP, Boulassel MR, Tremblay C, Routy JP, Bernard
N, Balderas R, Haddad EK, Sekaly RP: CD160 and PD-1 co-expression on
HIV-specific CD8 T cells defines a subset with advanced dysfunction.
PLoS Pathog 2012, 8:e1002840.
15. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, Pircher H, Thimme R:
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific
El-Far et al. Journal of Translational Medicine 2014, 12:217 Page 16 of 16
http://www.translational-medicine.com/content/12/1/217CD8+ T cells is linked to antigen recognition and T cell differentiation.
PLoS Pathog 2010, 6:e1000947.
16. Maiza H, Leca G, Mansur IG, Schiavon V, Boumsell L, Bensussan A: A novel
80-kD cell surface structure identifies human circulating lymphocytes
with natural killer activity. J Exp Med 1993, 178:1121–1126.
17. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD,
Patel AT, Robertson MJ, Nadler LM, Freeman GJ: Cloning of BY55, a novel
Ig superfamily member expressed on NK cells, CTL, and intestinal
intraepithelial lymphocytes. J Immunol 1998, 161:2780–2790.
18. Giustiniani J, Bensussan A, Marie-Cardine A: Identification and
characterization of a transmembrane isoform of CD160 (CD160-TM), a
unique activating receptor selectively expressed upon human NK cell
activation. J Immunol 2009, 182:63–71.
19. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, Bolton W,
Ogg G, Boumsell L, Bensussan A: Cutting edge: MHC class I triggering by
a novel cell surface ligand costimulates proliferation of activated human
T cells. J Immunol 1999, 162:1223–1226.
20. Le Bouteiller P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A,
Aguerre-Girr M, Rabot M, Hilgert I, Mami-Chouaib F, Tabiasco J, Boumsell L,
Bensussan A: Engagement of CD160 receptor by HLA-C is a triggering
mechanism used by circulating natural killer (NK) cells to mediate
cytotoxicity. Proc Natl Acad Sci U S A 2002, 99:16963–16968.
21. Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, Schiavon V,
Bensussan A, Le Bouteiller P: Cutting edge: engagement of CD160 by its
HLA-C physiological ligand triggers a unique cytokine profile secretion
in the cytotoxic peripheral blood NK cell subset. J Immunol 2004,
173:5349–5354.
22. Tsujimura K, Obata Y, Matsudaira Y, Nishida K, Akatsuka Y, Ito Y,
Demachi-Okamura A, Kuzushima K, Takahashi T: Characterization of
murine CD160+ CD8+ T lymphocytes. Immunol Lett 2006, 106:48–56.
23. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ: CD160
inhibits activation of human CD4+ T cells through interaction with
herpesvirus entry mediator. Nat Immunol 2008, 9:176–185.
24. del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI: HVEM/LIGHT/
BTLA/CD160 cosignaling pathways as targets for immune regulation.
J Leukoc Biol 2010, 87:223–235.
25. Tamada K, Shimozaki K, Chapoval AI, Zhai Y, Su J, Chen SF, Hsieh SL, Nagata S,
Ni J, Chen L: LIGHT, a TNF-like molecule, costimulates T cell proliferation
and is required for dendritic cell-mediated allogeneic T cell response.
J Immunol 2000, 164:4105–4110.
26. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A:
Herpesvirus entry mediator, a member of the tumor necrosis factor
receptor (TNFR) family, interacts with members of the TNFR-associated
factor family and activates the transcription factors NF-kappaB and AP-1.
J Biol Chem 1997, 272:14029–14032.
27. Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, Tan KB, Dede K,
Spampanato J, Silverman C, Hensley P, DiPrinzio R, Emery JG, Deen K, Eichman
C, Chabot-Fletcher M, Truneh A, Young PR: Herpesvirus entry mediator ligand
(HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells
and inhibits HT29 cell growth. J Biol Chem 1998, 273:27548–27556.
28. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA,
Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM:
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and
PD-1. Nat Immunol 2003, 4:670–679.
29. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S,
Pfeffer K, Ware CF, Murphy TL, Murphy KM: B and T lymphocyte attenuator
regulates T cell activation through interaction with herpesvirus entry
mediator. Nat Immunol 2005, 6:90–98.
30. Kojima R, Kajikawa M, Shiroishi M, Kuroki K, Maenaka K: Molecular basis for
herpesvirus entry mediator recognition by the human immune
inhibitory receptor CD160 and its relationship to the cosignaling
molecules BTLA and LIGHT. J Mol Biol 2011, 413:762–772.
31. Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ,
Giustiniani J, Bellard E, Brayer S, Aguerre-Girr M, Meggetto F, Giuriato S,
Malecaze F, Galiacy S, Jais JP, Chose O, Kadouche J, Chouaib S, Teissie J,
Abitbol M, Bensussan A, Le Bouteiller P: A novel antiangiogenic and vascular
normalization therapy targeted against human CD160 receptor. J Exp Med
2011, 208:973–986.
32. Abecassis S, Giustiniani J, Meyer N, Schiavon V, Ortonne N, Campillo JA,
Bagot M, Bensussan A: Identification of a novel CD160+ CD4+ T-lymphocytesubset in the skin: a possible role for CD160 in skin inflammation. J Invest
Dermatol 2007, 127:1161–1166.
33. Nikolova M, Marie-Cardine A, Boumsell L, Bensussan A: BY55/CD160 acts as
a co-receptor in TCR signal transduction of a human circulating cytotoxic
effector T lymphocyte subset lacking CD28 expression. Int Immunol 2002,
14:445–451.
34. Otsuki N, Kamimura Y, Hashiguchi M, Azuma M: Expression and function of
the B and T lymphocyte attenuator (BTLA/CD272) on human T cells.
Biochem Biophys Res Commun 2006, 344:1121–1127.
35. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K,
Dyer WB, Kim M, de Rose R, Kent SJ, Jiang L, Breit SN, Emery S, Cunningham
AL, Cooper DA, Kelleher AD: High levels of human antigen-specific CD4+
T cells in peripheral blood revealed by stimulated coexpression of CD25
and CD134 (OX40). J Immunol 2009, 183:2827–2836.
36. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung TC, Yu GL, Ruben S,
Murphy M, Eisenberg RJ, Cohen GH, Spear PG, Ware CF: LIGHT, a new
member of the TNF superfamily, and lymphotoxin alpha are ligands for
herpesvirus entry mediator. Immunity 1998, 8:21–30.
37. Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W,
Eaton DL: A coreceptor interaction between the CD28 and TNF receptor
family members B and T lymphocyte attenuator and herpesvirus entry
mediator. Proc Natl Acad Sci U S A 2005, 102:1116–1121.
38. Giustiniani J, Marie-Cardine A, Bensussan A: A soluble form of the MHC
class I-specific CD160 receptor is released from human activated NK
lymphocytes and inhibits cell-mediated cytotoxicity. J Immunol 2007,
178:1293–1300.
39. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S,
Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T,
Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD,
Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD,
Goulder PJ: Dominant influence of HLA-B in mediating the potential
co-evolution of HIV and HLA. Nature 2004, 432:769–775.
40. Harari A, Cellerai C, Enders FB, Kostler J, Codarri L, Tapia G, Boyman O,
Castro E, Gaudieri S, James I, John M, Wagner R, Mallal S, Pantaleo G:
Skewed association of polyfunctional antigen-specific CD8 T cell populations
with HLA-B genotype. Proc Natl Acad Sci U S A 2007, 104:16233–16238.
41. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC,
Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsacker F,
Roggendorf M, Kelleher D, Klenerman P, Blum HE, Thimme R: Dominant
influence of an HLA-B27 restricted CD8+ T cell response in mediating
HCV clearance and evolution. Hepatology 2006, 43:563–572.
doi:10.1186/s12967-014-0217-y
Cite this article as: El-Far et al.: CD160 isoforms and regulation of CD4
and CD8 T-cell responses. Journal of Translational Medicine 2014 12:217.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
